期刊
VIRUSES-BASEL
卷 13, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/v13102069
关键词
norovirus; protease; structure; antivirals
类别
资金
- National Institutes of Health [PO1 AI 057788]
- Robert Welch Foundation [Q1279]
Human norovirus (HuNoV) infection is a global health and economic burden with no licensed vaccines or antiviral drugs available. Developing HuNoV protease inhibitors by targeting the enzyme's active site faces challenges due to subtle differential conformational flexibility and structural differences in the active site and substrate-binding pockets. Further comparative analysis of available HuNoV protease structures is needed to identify novel strategies for effective inhibitor design and development.
Human norovirus (HuNoV) infection is a global health and economic burden. Currently, there are no licensed HuNoV vaccines or antiviral drugs available. The protease encoded by the HuNoV genome plays a critical role in virus replication by cleaving the polyprotein and is an excellent target for developing small-molecule inhibitors. The current strategy for developing HuNoV protease inhibitors is by targeting the enzyme's active site and designing inhibitors that bind to the substrate-binding pockets located near the active site. However, subtle differential conformational flexibility in response to the different substrates in the polyprotein and structural differences in the active site and substrate-binding pockets across different genogroups, hamper the development of effective broad-spectrum inhibitors. A comparative analysis of the available HuNoV protease structures may provide valuable insight for identifying novel strategies for the design and development of such inhibitors. The goal of this review is to provide such analysis together with an overview of the current status of the design and development of HuNoV protease inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据